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Results: 
 
 
Figure 1. An example of a patient with large variation in 
bladder filling between planning CT (thin light green) and 
CBCT before a treatment fraction (thick light green). The 
planning-CT and CBCT are matched to bony anatomy. (Red 
=CTV, blue=PTV, dark green= rectum) 
The bladder volumes varied widely both within each patient 
(see example in Fig. 1), between patients in the same group 
and between the groups. 
The individual patient mean bladder volume varied from 
79±23 to 269±90 ml in group 1 and between 64±19 to 309±110 
ml in group 2. 
Furthermore, there was no difference in the group mean 
bladder volume between the groups, 138±82 ml in group 1 
and 150±92 ml in group 2 (p-value 0,59). 
 
Conclusion: The findings indicate that the use of a strict 
bladder protocol is not superior to a comfortably filled 
bladder-regime to ensure a consistent bladder volume 
throughout the whole treatment course. The conclusion 
would be to let the patient prepare according to his own 
preference with a comfortably filled bladder. This could 
result in an easier patient setup due to a more relaxed 
patient. The impact of the wide variations in bladder volume 
on toxicity and dose distribution is further to be determined. 
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Purpose or Objective: To compare patient-reported 
outcomes (PROs) with physician-assessed outcomes (PAOs) on 
gastrointestinal (GI) dysfunction pre- and post-radiotherapy 
(RT) for locally advanced prostate cancer. 
 
Material and Methods: Adverse GI effects were assessed in 
80 subjects treated with intensity-modulated RT for locally 
advanced prostate cancer (78 Gy/56 Gy in 39 fractions to the 
prostate/pelvic lymph nodes) in 2011-2012. A study-specific 
PRO and CTCAE.v.3-based PAOs were completed pre- and 
post-RT (end, 3, 6, 12, and 24 m). This study focuses on the 
18 (PROs) and 8 (PAOs) potentially RT-induced GI symptoms. 
Symptomatic subjects were considered as having PRO>Grade 
1 and PAO>Grade 0 symptom severity. Relative risk ratios 
(RR) with related 95% confidence intervals (95%CI), and p-
values (two-sided 5% significance level) were calculated for 
each symptom and follow-up time post-RT, with pre-RT 
symptom severity as the reference. 
 
Results: Across all follow-up times, significant RRs were 
observed for in total 4/18 (RR: 2-25; p<0.001-0.02) PROs and 
1/8 (RR: 2; p=0.0001-0.02) PAO (Table). Defecation urgency 
and Obstruction yielded the tightest 95%CI among the PROs, 
and Flatulence among the PAOs. The RR indicated that the 
PROs acknowledged both acute (12 symptoms) and late (3m: 
5; 6m: 4; 12m: 7; 24m: 9 symptoms) RT-induced effects, and 
that the PAOs typically focused on acute rather than late 
effects (7 vs. 1-3 symptoms). 
 
 
 
Conclusion: This study indicates that the number of 
symptoms and temporal patterns of RT-induced GI 
dysfunction in locally advanced prostate cancer depend on 
the applied assessment method. Physician-assessed outcomes 
according to CTCAE.v.3 captured acute effects, and in 
particular flatulence, whilst patient-reported outcomes 
captured both acute and late effects mainly related to 
defecation urgency and obstruction. 
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Purpose or Objective: The aim of this paper is to analyze, in 
prostate cancer patients treated with external beam 
radiotherapy (EBRT), the prognostic factors and their impact 
on the outcome in terms of Cancer Specific Overall Survival 
(CSOS), Biochemical Disease Free Survival (BDFS) and Clinical 
Disease Free Survival (CDFS). 
 
Material and Methods: From October 1999 and March 2012 
we treated by EBRT, 1080 prostate cancer patients. The 
mean age was 69.2 years. Pretreatment staging examinations 
were: digital rectal examination (DRE), pretreatment PSA 
(iPSA), abdominal ultrasound, abdominal CT scan and bone 
scan. The 87% of patients were classified as < cT2, 87% had a 
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Gleason Score (GS) < 7; the mean of iPSA was 18 ng/mL; the 
rate of clinical positive nodes was 1%. The ADT was 
prescribed to 69% of patients in neoadjuvant setting, 65% in 
concomitant setting and 34% in adjuvant setting. The mean 
follow-up was 81 months.  
 
Results: The prognostic factors resulted statistically 
significant for all groups of patients at both, univariate and 
multivariate analysis, were the GS and the iPSA. In 
intermediate and high/very-high risk patients at multivariate 
analysis the prognostic factors for CSOS were: GS (p=0.001), 
positive lymph nodes on CT scan (p=0.05) and rectal 
preparation during the treatment (p=0.005); for the BDFS 
were: GS (p=0.008), patient risk classification (p=0.037), 
positive lymph nodes on CT scan (p=0.004), iPSA (p=0.001) 
and rectal/bladder preparation during the radiation 
treatment (p=0.001); for the CDFS were: number of positive 
core on biopsy (p=0.003), GS (p=0.0003), positive lymph 
nodes on CT scan (p=0.015), iPSA (p=0.0056) and RT dose 
(p=0.001). In high/very-high risk patient group at 
multivariate analysis the prognostic factors for CSOS were: 
biopsic Gleason Score, clinical/radiological stage, RT dose; 
for BDFS were: biopsic Gleason Score, adjuvant ADT, 
clinical/radiological stage, iPSA and RT dose>77.7 Gy; for 
CDFS were: biopsic Gleason Score, clinical/radiological stage, 
iPSA and RT dose>77.7 Gy. 
 
Conclusion: Our results confirm several prognostic factors 
already described by literature, adding a new prognostic 
factor represented by the rectal/bladder preparation, 
generally known for its effect on toxicity but not yet on 
outcome. We believe that in the future a new nomogram 
should include also some therapeutic variables (as RT dose, 
RT technique and ADT), to help clinicians in decision-making. 
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Purpose or Objective: We aim to evaluate the biochemical 
failure free survival (BFFS) and morbidity in high risk prostate 
cancer patients treated with long term androgen deprivation 
therapy (ADT) and hypofractionated Simultaneous Integrated 
Boost (SIB) IMRT. Recent advances in techniques enable us to 
deliver a higher dose of radiation to the prostate with limited 
dose to the adjacent rectum and bladder. Earlier studies 
have estimated prostate cancer to have low α/β of 1.5. Thus 
hypofractionated schedules in theory should confer better 
local control and cancer specific survival (CSS). Due to the 
long natural history of prostate cancer it becomes imperative 
to reduce rectal and bladder morbidity. Also BFFS has shown 
to be a predictor of CSS. Most of the studies with whole 
pelvic RT and long term ADT have used conventional 
fractionation schedules. Data on the benefit of 
hypofractionated SIB IMRT with long term ADT is limited.  
 
Material and Methods: Retrospective analysis of 100 high risk 
prostate cancer patients treated between 2010-2012. All 
patients received SIB IMRT with 70Gy in 28 fractions to the 
prostate and seminal vesicles (if involved ) and 50.4 Gy in 28 
fractions to the pelvic nodal stations with neoadjuvant 
hormonal therapy for a duration of 3-6 months prior to 
radiation and adjuvant hormonal therapy for a duration of 
24-36 months. They were followed up with serial PSA values 
and clinical examination. Biochemical failure was defined as 
serum PSA >nadir + 2 (ASTRO Phoenix definition). Acute 
rectal and bladder toxicity was scored with the RTOG toxicity 
criteria. Chronic rectal toxicity (proctitis) and chronic 
bladder toxicity (cystitis ) were assessed using the CTCAE 4.0. 
Patients without biochemical failure were censored at last 
follow-up/last PSA check or death. BFFS was calculated by 
the Kaplan-Meier method. 
 
Results: At a median follow up of 45 months (20-87 months ), 
there were 13 cases of biochemical failure (13 %) . 5 year 
BFFS was 78.6% .There was no Grade 3 or 4 acute rectal or 
bladder toxicity . Chronic toxicity has been listed in the table 
below. Urethral stricture developed in 7 patients, of whom 6 
had prior TURP showing significant correlation 
(6/15,p<0.001). 
 
 
 
 Grade 2  Grade 3  Grade 4  
Proctitis  12  2 0 
Cystitis  7 0 0 
 
Conclusion: This study therefore concludes that long term 
ADT and SIB IMRT provides a feasible alternative to 
conventional radiation therapy with good biochemical control 
and acceptable toxicity. Longer follow up of these patients 
would provide data on cancer specific survival and late 
morbidity.  
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Purpose or Objective: A status of disease with a limited 
number of distant lesions and a controlled primitive tumor is 
recently defined as oligo-recurrence: this group of patients is 
more favorable than the other with a high number of 
metastases and, in prostate cancer, often is represented by a 
single node.The objective of this retrospective study was to 
evaluate the acute and late toxicity rates, in salvage 
stereotactic body radiation therapy (SBRT) as a treatment 
modality in nodes oligo-recurrence, from prostate cancer. 
 
Material and Methods: Between February 2013 and March 
2015, 21 patients, for a total of 29 isolated lymph nodes from 
prostate cancer, were treated with SBRT, delivered with 
Truebeam Stx (Varian®), at UPMC San Pietro FBF 
radiotherapy center of Rome.The median age at primitive 
diagnoses was 65 (range 50-74) years. For the primary 
treatment, radical prostatectomy and postoperative 
irradiation, exclusive radiotherapy or prostatectomy was 
performed in 12 (57%) patients, 7 patients (33%) and 2 
patients (10%), respectively. Median previous RT dose was 72 
Gy/35 fractions.Median PSA at the time of recurrence was 
2.04ng/ml.All patients with arising PSA underwent a [11C] 
choline-positron emission tomography before SBRT, in order 
to exclude other sites of disease. The SBRT dose varied from 
27 to 30 Gy, in 1-5 daily fractions, according to the previous 
RT treatment for the primitive lesion or a close organ at risk. 
A daily cone-beam CT and X-ray (BRAINLAB ExacTrac®) scans 
were acquired before each treatment session, for every 
